A Study of IBI362 in Chinese Patients With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.
Also called NCT04965506
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 252 participants
- Registry
-
NCT04965506
-
- Other papers using this trial's data
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04965506. Randomized; double masking; primary purpose treatment. Start 2021-09-06 (actual); primary completion 2022-04-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of IBI362 in Chinese Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- IBI362
- Intervention (Other)
- placebo
- Intervention (Other)
- Dulaglutide
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Record details
- Record id
cardio:ct-nct04965506- Content hash
9c4cd4b64f55b3340651f4949ed39ac599a0af51fe579f4bd14b6340bf52268c